The impact of good mental health in the financial services industry

Our report presents all the evidence you’ll need to make the business case for investing in employee mental health.

From burnt-out bank bosses, to insurance brokers isolated at home, the financial sector is suffering a surge in mental health issues exacerbated by the COVID-19 pandemic. Unfortunately, financial services companies often lack the clarity and resources necessary to make the business case for investing in employee mental health. Not anymore.

Employees suffering from insomnia or anxiety are costing firms, on average, over 2.5 times as much as their healthy counterparts; a staggering difference of $7,927 per employee.
Claims data from 25 self-insured employers

Our new industry-specific report demystifies how to quantify the value of better employee mental health so that you don’t have to.

You’ll learn:

  • How improved mental health impacts your organization’s bottom line
  • Why helping your employees access effective care is a good financial decision
  • What barriers to mental health care are most problematic for your workforce —and proven ways to break them down.
  • How your organization can think strategically about investing in workplace mental health

A peek inside:

Copy Link

Download the report

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023